Health Care / BiotechTechnical Analysis Guide

REGN Stock Analysis

Regeneron Pharmaceuticals, Inc.

💡 Quick Answer

Across 4 APEX technical signals, REGN is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-07-08. Run a live analysis to see the current composite score.

REGN runs ATR of 2.5-4% and trades on Dupixent growth, Eylea competition (biosimilar erosion and Eylea HD conversion), and pipeline readouts. High share price keeps daily volume modest.

RSI Behavior: Range 38-72MACD Pattern: Catalyst-influencedMoving Average: 200-day trend guide

Regeneron makes Dupixent (allergy, eczema, asthma, COPD) in partnership with Sanofi and Eylea for retinal eye disease, with a deep antibody pipeline. Dupixent's label-expansion trajectory and Eylea HD's defense against biosimilars are the core earnings drivers.

LIVE CHART·REGN. DailyPowered by TradingView

Open REGN on TradingView ↗Affiliate link

Get live REGN signal analysis

APEX runs 8 signals on REGN in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze REGN Now →

Why Do Traders Watch REGN?

REGN runs ATR of 2.5-4% and trades on Dupixent growth, Eylea competition (biosimilar erosion and Eylea HD conversion), and pipeline readouts. High share price keeps daily volume modest. Clinical-trial data drives 5-15% gaps.

Is REGN a Buy Right Now? Current Signal Readings

📊RSI BehaviorRange 38-72

RSI dips toward 40 on Eylea-competition fears have been entries when Dupixent growth offset the erosion. Positive pipeline data pushes it toward overbought.

📈MACD PatternCatalyst-influenced

MACD works between clinical catalysts. Major trial readouts and label decisions can override technical signals abruptly.

📊Moving Average200-day trend guide

The 200-day frames the trend. Breaks below it have tracked Eylea-erosion concern; reclaims follow Dupixent or pipeline wins.

📦Volume ProfileData and earnings driven

Volume spikes on trial readouts, FDA decisions, and earnings. High share price keeps baseline volume low.

📋 REGN Key Stats for Traders

⚡ATR (14-day)2.5-4% of price

📦Avg daily volume~500k-900k shares

🎯Key metricDupixent growth + Eylea defense

⚠️Risk levelMedium

🔗 Related Stocks

VRTXAMGN GILD BIIB

Run a live REGN analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze REGN Free →

Advanced charting for REGN on TradingView ↗

💬 Frequently Asked Questions. REGN

QIs REGN a good stock to buy right now?

AWhether REGN is a buy depends on its current technical positioning. REGN runs ATR of 2.5-4% and trades on Dupixent growth, Eylea competition (biosimilar erosion and Eylea HD conversion), and pipeline readouts. High share price keeps daily volume modest. Clinical-trial data drives 5-15% gaps. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for REGN?

AThe four key signals for REGN are: RSI Behavior (Range 38-72). RSI dips toward 40 on Eylea-competition fears have been entries when Dupixent growth offset the erosion. Positive pipeline data pushes it toward overbought.. MACD Pattern (Catalyst-influenced). MACD works between clinical catalysts. Major trial readouts and label decisions can override technical signals abruptly.. Moving Average (200-day trend guide). The 200-day frames the trend. Breaks below it have tracked Eylea-erosion concern; reclaims follow Dupixent or pipeline wins.. Volume Profile (Data and earnings driven). Volume spikes on trial readouts, FDA decisions, and earnings. High share price keeps baseline volume low.

QWhat is REGN's RSI telling traders right now?

ARSI dips toward 40 on Eylea-competition fears have been entries when Dupixent growth offset the erosion. Positive pipeline data pushes it toward overbought. APEX scores REGN's RSI as part of its 8-factor composite signal. Updated daily.

QHow does REGN behave technically compared to other Health Care / Biotech stocks?

AREGN is in the Health Care / Biotech sector. Regeneron makes Dupixent (allergy, eczema, asthma, COPD) in partnership with Sanofi and Eylea for retinal eye disease, with a deep antibody pipeline. Dupixent's label-expansion trajectory and Eylea HD's defense against biosimilars are the core earnings drivers. Key stats: ATR (14-day): 2.5-4% of price, Avg daily volume: ~500k-900k shares, Key metric: Dupixent growth + Eylea defense, Risk level: Medium.

QWhat MACD signals work best for REGN?

AMACD works between clinical catalysts. Major trial readouts and label decisions can override technical signals abruptly.

OTHER STOCK GUIDES

Technology49

+−